GlassScriptPhysician profile
Darel Butler
NPI 1154403426
$1,021.18
in general payments reported to CMS, 2019-2025
14 companies · $832 in 2025
The $832 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $83.97 · 2024: $105 · 2025: $832.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $793 · Education: $144.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $793.22 |
| Education | $143.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $445.97 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $289.08 | 2019-2025 | Austedo Xr, Ajovy |
| Ucb, INC. | $36.37 | 2025 | Rystiggo |
| Acadia Pharmaceuticals INC | $31.95 | 2025 | Nuplazid |
| Biogen, INC. | $29.15 | 2025 | Tysabri, Vumerity |
| Janssen Biotech, INC. | $28.82 | 2025 | |
| Emd Serono, INC. | $26.88 | 2025 | |
| Adamas Pharmaceuticals, INC. | $24.80 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $22.57 | 2025 | Rexulti |
| Ani Pharmaceuticals, INC. | $19.70 | 2025 | Purified Cortrophin Gel |
| Zoll Respicardia, INC. | $17.97 | 2024 | Remede System |
| Livanova USA, INC. | $16.10 | 2019 | |
| Assertio Therapeutics, INC. | $15.92 | 2019 | |
| Amgen INC. | $15.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darel Butler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.